View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Current Fiscal Year End Date	--12-31
Trading Symbol	stxs
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		19,308,125
Entity Public Float			$ 6.8

Balance Sheets - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 13,775,130	$ 7,777,718
Accounts receivable, net of allowance of $383,077 and $640,183 in 2013 and 2012, respectively	7,558,152	11,570,489
Inventories	4,879,039	5,098,241
Prepaid expenses and other current assets	1,945,206	3,492,067
Total current assets	28,157,527	27,938,515
Property and equipment, net	1,184,589	2,141,923
Intangible assets, net	1,679,486	1,979,320
Long-term receivables	20,431	73,199
Other assets	34,363	32,987
Total assets	31,076,396	32,165,944
Current liabilities:
Short-term debt and current maturities of long-term debt	49,733	12,264,490
Accounts payable	3,512,339	3,556,688
Accrued liabilities	7,079,381	5,361,810
Deferred revenue	7,519,754	9,502,939
Warrants and debt conversion features	5,644,626	2,968,348
Total current liabilities	23,805,833	33,654,275
Long-term debt, less current maturities	18,481,478	16,824,736
Long-term deferred revenue	491,080	477,159
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2013 and 2012
Common stock, par value $0.001; 300,000,000 shares authorized, 19,311,390 and 8,018,615 shares issued at 2013 and 2012, respectively	19,311	8,019
Additional paid in capital	441,888,155	366,053,627
Treasury stock, 4,015 shares at 2013 and 2012	(205,999)	(205,999)
Accumulated deficit	(453,403,462)	(384,645,873)
Total stockholders' deficit	(11,701,995)	(18,790,226)
Total liabilities and stockholders' deficit	$ 31,076,396	$ 32,165,944

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 383,077	$ 640,183
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	19,311,390	8,018,615
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	12 Months Ended
Statements Of Operations - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue:
Systems	$ 12,743,218	$ 19,672,983	$ 15,585,538
Disposables, service and accessories	25,287,863	26,889,451	26,401,894
Total revenue	38,031,081	46,562,434	41,987,432
Cost of revenue:
Systems	6,870,954	9,905,528	8,576,283
Disposables, service and accessories	4,130,347	4,875,527	3,921,798
Total cost of revenue	11,001,301	14,781,055	12,498,081
Gross margin	27,029,780	31,781,379	29,489,351
Operating expenses:
Research and development	5,672,058	8,405,086	12,886,488
Sales and marketing	17,132,093	20,607,999	31,635,415
General and administrative	13,066,103	13,394,556	16,908,656
Total operating expenses	35,870,254	42,407,641	61,430,559
Operating loss	(8,840,474)	(10,626,262)	(31,941,208)
Other income (expense)	(47,349,378)	8,265,507	3,416,383
Interest income	5,800	7,361	9,052
Interest expense	(12,573,537)	(6,885,033)	(3,515,402)
Net loss	$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Net loss per common share:
Basic	$ (5.95)	$ (1.33)	$ (5.84)
Diluted	$ (5.95)	$ (1.33)	$ (5.84)
Weighted average shares used in computing net loss per common share:
Basic	11,554,566	6,944,928	5,482,627
Diluted	11,554,566	6,944,928	5,482,627

Statements Of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2010	$ 5,475	$ 354,052,041	$ (205,999)	$ (343,376,271)	$ 10,475,246
Shares, issued, beginning balance at Dec. 31, 2010	5,474,624
Issuance of common stock and warrants, value	$ 8	(8)
Issuance of common stock and warrants, shares	8,400
Share-based compensation, value		2,487,441			2,487,441
Issuance of stock under purchase plan, value	$ 9	232,382			232,391
Issuance of stock under purchase plan, shares	8,449
Exercise of stock options, value		7,202			7,202
Exercise of options/SAR's, shares	468
Grant of restricted shares, net of forfeitures, value	$ 51	(51)
Grant of restricted shares, net of forfeitures, shares	51,216
Net Loss				(32,031,175)	(32,031,175)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2011	$ 5,543	356,779,007	(205,999)	(375,407,446)	(18,828,895)
Shares, issued, ending balance at Dec. 31, 2011	5,543,157
Issuance of common stock and warrants, value	$ 2,415	10,409,260			10,411,675
Issuance of common stock and warrants, shares	2,415,339
Share-based compensation, value		2,293,731			2,293,731
Issuance of stock under purchase plan, value	$ 10	73,543			73,553
Issuance of stock under purchase plan, shares	10,315
Grant of restricted shares, net of forfeitures, value	$ 20	(20)
Grant of restricted shares, net of forfeitures, shares	19,885
Restricted stock vestings, value	$ 31	(31)
Restricted stock vestings, shares	29,919
Reclassification of warrants to liability		(3,501,863)			(3,501,863)
Net Loss				(9,238,427)	(9,238,427)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2012	$ 8,019	366,053,627	(205,999)	(384,645,873)	(18,790,226)
Shares, issued, ending balance at Dec. 31, 2012	8,018,615
Issuance of common stock and warrants, value	$ 7,743	64,586,770			64,594,513
Issuance of common stock and warrants, shares	7,742,717
Share-based compensation, value		1,050,260			$ 1,050,260
Exercise of options/SAR's, shares					145
Rights offering, value	$ 3,400	10,197,647			$ 10,201,047
Rights offering, shares	3,400,349
Grant of restricted shares, net of forfeitures, value	$ (62)	62
Grant of restricted shares, net of forfeitures, shares	(61,910)
Restricted stock vestings, value	$ 211	(211)
Restricted stock vestings, shares	211,619
Net Loss				(68,757,589)	(68,757,589)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2013	$ 19,311	$ 441,888,155	$ (205,999)	$ (453,403,462)	$ (11,701,995)
Shares, issued, ending balance at Dec. 31, 2013	19,311,390

Statements Of Cash Flows - USD ($)	12 Months Ended
Statements Of Cash Flows - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities
Net loss	$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	919,136	1,300,188	1,462,238
Amortization of intangibles	299,833	299,833	299,833
Amortization of deferred finance costs and debt discounts	7,703,336	2,977,119	1,331,549
Share-based compensation	1,050,260	2,293,731	2,487,441
Non-cash royalty (income), net			(2,353,718)
Gain on debt conversion		(75,612)
Loss on asset disposal	36,103	12,444	86,278
Adjustment of warrants and convertible debt features	47,450,066	(8,189,895)	(3,416,383)
Interest due from issuance of stock	551,296	192,128
Changes in operating assets and liabilities:
Accounts receivable	4,013,279	(447,613)	2,811,531
Other receivables	51,827	19,534	28,495
Inventories	219,202	937,810	(594,576)
Prepaid expenses and other current assets	429,025	(760,474)	827,297
Other assets	(1,376)	7,773	(2,223)
Accounts payable	(44,349)	(2,053,493)	(3,186,001)
Accrued liabilities	1,717,571	(514,689)	(1,090,072)
Deferred revenue	(1,969,264)	1,125,079	1,775,856
Other liabilities		(3,094)	(5,648)
Net cash used in operating activities	(6,331,644)	(12,117,658)	(31,569,278)
Cash flows from investing activities
Purchase of equipment		(130,699)	(1,031,749)
Net cash used in investing activities		(130,699)	(1,031,749)
Cash flows from financing activities
Payments of term note	(4,000,000)	(4,000,000)	(2,000,000)
Proceeds from revolving line of credit	37,237,131	54,806,154	77,109,376
Payments of revolving line of credit	(44,490,148)	(62,842,934)	(72,818,866)
Proceeds from subordinated convertible debt, net of issuance costs		7,738,351
Proceeds from Healthcare Royalty Partners debt	2,546,328	2,500,000	14,317,397
Payments of Healthcare Royalty Partners debt	(263,192)	(1,252,647)
Payments of Biosense Debt			(5,540,373)
Proceeds from issuance of stock and warrants, net of issuance costs	21,298,937	9,122,232	239,593
Net cash provided by financing activities	12,329,056	6,071,156	11,307,127
Net increase (decrease) in cash and cash equivalents	5,997,412	(6,177,201)	(21,293,900)
Cash and cash equivalents at beginning of period	7,777,718	13,954,919	35,248,819
Cash and cash equivalents at end of period	13,775,130	7,777,718	13,954,919
Supplemental disclosures of cash flow information:
Interest Paid	$ 3,187,353	$ 3,258,900	$ 859,494

Description Of Business	12 Months Ended
Description Of Business	Dec. 31, 2013
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”). The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; V-Sono ICE Catheter Manipulator has received U.S. regulatory clearance and the V-Loop Circular Catheter Manipulator is expected to be submitted for review by the U.S. Food and Drug Administration in early 2014. Since our inception, we have generated significant losses. As of December 31 2013, we had incurred cumulative net losses of approximately $453.4 million. In May 2011, the Company introduced the Niobe ES system and as of December 31, 2013, the Company had an installed base of 100 Niobe ES systems and has received positive feedback from the physicians at these sites. Between 2011 and 2013, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15% to 20% on an annual run rate basis. We expect to incur additional losses into 2014 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives. During 2014, we expect operating expenses to be generally consistent with 2013 with additional investment in certain targeted areas. We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities and working capital and equipment financing loans. In the future, we may finance cash needs through the sale of other equity securities or non-core assets, strategic collaboration agreements, debt financings or through distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control. Our existing cash, cash equivalents and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing before that time. Further, our revolving line of credit with Silicon Valley Bank matures on March 31, 2014. We cannot assure that additional financing will be available on a timely basis on terms acceptable to us or at all, or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, we could be required to cease operations.

Summary Of Significant Accounting Policies	12 Months Ended
Summary Of Significant Accounting Policies	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. In 2012, we entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015. No cash was restricted at December 31, 2013 or 2012. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Property and Equipment Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2013 or 2012 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Net Loss per Common Share Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2013, 2012, and 2011 are presented on a post-split basis. See Note 11 for additional discussion of the reverse stock split. As of December 31, 2013, the Company had 188,947 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $48.38 per share and 3,021,302 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $14.21 per share. The Company had a weighted average of 33,058 unearned restricted shares outstanding for the period ended December 31, 2013. Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. One customer, Biosense Webster Inc., as our distributor, accounted for $3,902,178, $3,447,386, and $3,663,687, or 10%, 7% and 9%, of total net revenue for the years ended December 31, 2013, 2012, and 2011, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2013. Reclassifications Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split. Recently Issued Accounting Pronouncements In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU” or “Update”) 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”). The update requires that the Company present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI based on its source and the income statement line items affected by the reclassification. The guidance is effective for interim and annual reporting periods beginning on or after December 15, 2012. As the Company has no items of other comprehensive income, the Company is not required to report accumulated other comprehensive income. In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-11, “Disclosures about Offsetting Assets and Liabilities.” The Update enhances the disclosure of offsetting assets and liabilities by requiring companies to disclose both the gross and net information about instruments and transactions eligible for offset as well as those subject to an agreement similar to master netting arrangements. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2013. The adoption of this pronouncement did not have an impact on the financial statements. In June 2011, the FASB issued new accounting guidance related to the presentation of comprehensive income that increases comparability between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance eliminates the current option to report other comprehensive income (OCI) and its components in the statement of changes in stockholders’ equity. This guidance was effective for the Company’s interim and annual periods beginning January 1, 2012. As the Company has no items of other comprehensive income, the Company is not required to report comprehensive income or other comprehensive income. In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS.” The Update amends the guidance on fair value measurements to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The Update does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting. This guidance was effective during interim and annual periods beginning after December 15, 2011. The adoption of this ASU did not have a material effect on our financial position or results of operations.

Inventory

12 Months Ended

Dec. 31, 2013

Inventory [Abstract]

Inventory

3. Inventory

Inventory consists of the following:


	December 31, 2013	December 31, 2012

Raw materials	$ 3,141,111	$ 3,303,053
Work in process	364,779	65,546
Finished goods	1,453,362	1,802,281
Reserve for obsolescence	(80,213)	(72,639)
Total inventory	$ 4,879,039	$ 5,098,241

Prepaid Expenses And Other Current Assets

12 Months Ended

Dec. 31, 2013

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2013	December 31, 2012

Prepaid expenses	$ 591,305	$ 330,756
Deferred cost of revenue	72,699	527,725
Derivative asset	—	1,736
Deferred financing costs	622,949	1,590,916
Deposits	658,253	1,040,934
Total prepaid expenses and other current assets	$ 1,945,206	$ 3,492,067

Deferred cost of revenue represents the cost of systems for which risk of loss and or title has transferred from the Company but for which revenue has not been recognized.

The derivative asset represents the fair value of a debt conversion feature that is part of the subordinated convertible debentures agreement. Refer to Notes 9 and 12 for discussion of the debentures and fair value measurement, respectively.

Property And Equipment

12 Months Ended

Dec. 31, 2013

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	December 31,	December 31,
	2013	2012

Equipment	$ 8,143,000	$ 8,762,041
Equipment held for lease	303,412	303,412
Leasehold improvements	2,328,381	2,328,381
	10,774,793	11,393,834
Less: Accumulated depreciation	(9,590,204)	(9,251,911)
Net property and equipment	$ 1,184,589	$ 2,141,923

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2013
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets As of December 31, 2013 and 2012, the Company had total intangible assets of $3,665,000. Accumulated amortization at December 31, 2013 and 2012, was $1,985,514 and 1,685,680. Amortization expense for the years 2013, 2012, and 2011 was $299,833 per year, as determined under the straight-line method. The estimated future amortization of intangible assets is $299,833 annually through July 2018, decreasing thereafter to $166,500 annually through May 2020.

Accrued Liabilities

12 Months Ended

Dec. 31, 2013

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	December 31,	December 31,
	2013	2012

Accrued salaries, bonus, and benefits	$ 3,565,385	$ 2,123,167
Accrued rent	1,499,942	1,095,641
Accrued warranties	501,212	653,473
Accrued interest	498,058	469,049
Accrued licenses and maintenance fees	302,384	323,901
Accrued taxes	360,475	245,802
Other	351,925	450,777
Total accrued liabilities	$ 7,079,381	$ 5,361,810

Deferred Revenue

12 Months Ended

Dec. 31, 2013

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	December 31,	December 31,
	2013	2012

Product shipped, revenue deferred	$ 1,368,007	$ 3,206,641
Customer deposits	421,544	558,227
Deferred service and license fees	6,221,283	6,215,230
	8,010,834	9,980,098
Less: Long-term deferred revenue	(491,080)	(477,159)
Total current deferred revenue	$ 7,519,754	$ 9,502,939

Long-Term Debt And Credit Facilities

12 Months Ended

Dec. 31, 2013

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:


	December 31, 2013		December 31, 2012
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due March 2014	$ -	$ -	$ 7,253,017	$ 7,277,084
Term note, due December 2013	—	—	4,000,000	4,000,000
Healthcare Royalty Partners debt	18,531,211	18,531,211	16,248,075	16,248,075
Subordinated convertible debentures	—	—	1,588,134	1,588,134
Total debt	18,531,211	18,531,211	29,089,226	29,113,293
Less current maturities	(49,733)	(49,733)	(12,264,490)	(12,288,557)
Total long term debt	$ 18,481,478	$ 18,481,478	$ 16,824,736	$ 16,824,736

Contractual principal maturities of debt at December 31, 2013 are as follows:



2014	$	49,733
2015		49,733
2016		49,733
2017		49,733
2018		18,332,279
2019 and Beyond		-
	$	18,531,211	(1)


(1) Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of December 31, 2013 and December 31, 2012. Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3). The carrying amounts of the Subordinated Convertible Debentures are net of the respective unamortized debt discount as of December 31, 2012.

The revolving line of credit and the Company’s obligations with Healthcare Royalty Partners II, L.P. (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is also required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Revolving line of credit

In November 2010, the Company received from stockholders, who at the time were affiliates of two members of our board of directors (“the Lenders”), an extension of their commitment to provide $10 million in either direct loans to the Company or loan guarantees to the Company’s primary bank lender through the earlier of March 31, 2012 or the date the Company receives $30 million of third party, non-bank financing, coincidental with the proposed maturity of the bank line of credit, as amended. The Company granted to the Lenders warrants to purchase 80,000 shares in exchange for their extension. The warrants are exercisable at $40.15 per share, beginning on March 1, 2011 and expiring on February 28, 2016. The fair value of these warrants of $1,747,392, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably. As the previous guarantee was no longer in effect, the Company expensed in 2010 the entire balance on the warrants issued to the Lenders in October 2009.

In December 2010, the Company further amended its agreement with its primary lender to extend the maturity of the current working capital line of credit from March 31, 2011 to March 31, 2012, retaining the $30 million total availability under the line per the 2009 amendment. The revised agreement retained the $10 million sublimit for borrowings supported by guarantees from the Lenders. Under the revised facility the Company was required to maintain a minimum “tangible net worth” and liquidity ratio as defined in the agreement. Interest on the facility accrued at the rate of prime plus 0.5% subject to a floor of 6% for the amount under guarantee and prime plus 1.75% subject to a floor of 7% for the remaining amounts.

In September 2011, the Company amended its agreement with its primary lender. The amendment reduced the availability amount of all credit extensions, other than the term loan, from $30 million to $20 million, and modified the interest rate applicable to the term loan from the lender’s prime rate plus 3.5% to the bank’s prime rate plus 5.5%.

On November 30, 2011, the Company entered into a Second Amended and Restated Loan and Security Agreement with its primary lender (“Amended Loan Agreement”). Under the Amended Loan Agreement, the Company agreed to revised tangible net worth and liquidity ratio covenants. Further, certain intellectual property assets of the Company were added to the collateral which secures repayment of the loan. Finally, the Amended Loan Agreement permits the Company to repay Healthcare Royalty Partners II, L.P. (“Healthcare Royalty Partners”), formerly “Cowen Healthcare Royalty Partners II, L.P.”, with the royalties due to the Company under the Biosense Agreement (the "Biosense Agreement"), as described below.

On March 30, 2012, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2012 to April 30, 2012 and reduced the Company’s borrowing availability by $3,333,333. The Company also received from the Lenders an extension of their commitment to provide $10 million in loan guarantees until April 30, 2012. As a result of this extension, the Company issued the Lenders warrants to purchase 75,735 shares of common stock at $6.60 per share.

On May 1, 2012, the Company and its primary lender entered into an agreement in which the lender extended the maturity of the revolving line of credit from April 30, 2012 to May 15, 2012. The Company and the Lenders also agreed to amend their agreement to extend the $10 million loan guarantee through May 15, 2012. The Company granted warrants to purchase an aggregate of 60,976 shares of common stock at $4.10 per share in exchange for the extension of the guarantee.

On May 10, 2012, upon closing of financing transactions for gross proceeds of $18.5 million, the Company entered into the Third Loan Modification Agreement with its primary lender. The amendment extended the revolving credit facility maturity to March 31, 2013 and revised the financial covenants. Additionally, the revolving line of credit was decreased from $20 million to $13 million. The reduction was as a result of the pay down of $7 million of the guarantees provided by the Lenders. In addition the Company and the Lenders agreed to decrease the $10 million guarantee to $3 million and to further extend the loan guarantee through March 31, 2013. The Company granted warrants to purchase an aggregate of 234,305 shares of common stock at $3.361 per share in exchange for the extension of the guarantee.

On March 29, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2013 to June 30, 2013. The Company and the Lenders also agreed to extend until June 30, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 113,636 shares of common stock at $1.98 per share.

On June 28, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from June 30, 2013 to July 31, 2013, and decreased the amount of available advances from $13 million to $6 million. In addition, the Bank waived the testing of the tangible net worth and liquidity ratio financial covenants under the Amended Loan Agreement for the period ended June 30, 2013. The Company and the Lenders also agreed to extend until July 31, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 48,387 shares of common stock at $1.55 per share.

On July 31, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from July 31, 2013 to August 31, 2013. In addition, the Bank waived the testing of the liquidity ratio financial covenant under the Amended Loan Agreement for the period ended July 31, 2013. The Company and the Lenders also agreed to extend until August 31, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 14,313 shares of common stock at $5.24 per share.

On August 30, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from August 31, 2013 to March 31, 2014. In addition, the Company and the Bank agreed to a reduction in the revolving credit line from $6.0 million to $3.0 million, the elimination of the $3.0 million sublimit guaranteed by the Lenders, and release of the guarantees by the Lenders in favor of the Bank. The amendment eliminated the prepayment premium for the prepayment of the term loan and modified the financial covenants to (a) eliminate the minimum tangible net worth covenant, (b) substitute in lieu thereof an EBITDA test, requiring the Company to maintain a minimum EBITDA of no less than (no worse than) (i) negative $4.0 million for the trailing three-month period ending September 30, 2013 and (ii) negative $3.0 million for the trailing three-month period ending December 31, 2013, in each case tested quarterly on a trailing three month basis, and (c) revise the liquidity ratio covenant to require the Company to maintain a liquidity ratio of greater than 2:1, excluding certain short term advances from the calculation.

As of December 31, 2013, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2013, the Company had a borrowing capacity of $3.0 million based on the Company’s collateralized assets. As such, the Company had ability to borrow $3.0 million under the revolving line of credit at December 31, 2013.

Term note

Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of prime plus 3.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably over the life of the term loan. The term note was paid in full in September 2013.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners II, L.P. (formerly “Cowen Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loans Agreement described above.

Subordinated Convertible Debentures

In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures (the “Debentures”), which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction. The purchasers of the Debentures also received warrants, which were scheduled to expire in November 2018, to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share. The Debentures bore interest at 8% per year and were scheduled to mature on May 7, 2014. In addition, the Company had the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and following the registration of the shares for resale, the Company issued shares in lieu of cash interest payments

The Company recorded the Debentures on the balance sheet net of the debt discount of $7.6 million. The debt discount was due to warrants issued in conjunction with the Debentures and the debt conversion features. Upon issuance of the Debentures, the fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively. The debt discount was amortized over the life of the loan using the effective interest method and the warrants and derivative liability were recorded at fair value on each reporting period. Refer to Note 12 for additional discussion of the fair value of the warrants and conversion features.

On August 7, 2013, holders of Convert Warrants exercised all of their Convert Warrants for an aggregate of approximately 2.5 million shares of our common stock, resulting in cash proceeds of approximately $8.5 million. In addition, holders of all of the Debentures exchanged the balance of their unconverted Debentures for an aggregate of approximately 2.7 million shares of the Company’s common stock and additional warrants (the “Exchange Warrants”) to purchase approximately 2.5 million shares, having an exercise price of $3.361 per share. On August 8, 2013, certain former holders of the Debentures exercised Exchange Warrants to purchase an aggregate of 1.4 million shares of common stock in cashless net exercises as provided for in the Exchange Warrants, which resulted in the issuance to such funds of an aggregate of 0.8 million shares of common stock but no net proceeds to the Company. The Company is relying on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, based on representations to the Company made by the warrant holders. Refer to Note 11 for discussion of total outstanding warrants.

The mark-to-market expense associated with the adjustment of warrants and convertible debt features in connection with the third quarter capital transactions are included in other expense for the year ended December 31, 2013. The write-off of the unamortized debt discount of $5.4 million is included in interest expense for the year ended December 31, 2013.

Biosense Webster Advance

In July 2008, the Company and Biosense Webster entered into an amendment to their existing agreements relating to the development and sale of catheters. Pursuant to the amendment, Biosense Webster agreed to pay to the Company $10.0 million as an advance on royalty amounts that were owed at the time the amendment was executed or would be owed in the future by Biosense Webster to the Company pursuant to the royalty provisions of one of the existing agreements. The Company and Biosense Webster also agreed that an aggregate of up to $8.0 million of certain agreed upon research and development expenses that were owed at the time the amendment was executed or may be owed in the future by the Company to Biosense Webster pursuant to the existing agreement would be deferred and would be due, together with any unrecouped portion of the $10.0 million royalty advance, no later than December 31, 2011. Interest on the outstanding and unrecouped amounts of the royalty advance and deferred research and development expenses accrued at an interest rate of the prime rate plus 0.75%. Outstanding royalty advances and deferred research and development expenses and accrued interest thereon were recouped by Biosense Webster by deductions from royalty amounts otherwise owed to the Company from Biosense Webster pursuant to the existing agreement. Approximately $18.0 million had been advanced by Biosense Webster to the Company pursuant to the amendment. As of December 31, 2011, these amounts plus interest accrued thereon had been repaid in full, in accordance with the agreement. The Company recorded research and development expenses of $1.1 million and disposables, service and accessories revenue of $3.6 million for the year ended December 31, 2011, related to this agreement.

Lease Obligations

12 Months Ended

Dec. 31, 2013

Lease Obligations [Abstract]

Lease Obligations

10. Lease Obligations

The Company leases its facilities under operating leases. For the years ended December 31, 2013, 2012, and 2011 rent expense was $1,925,813, $1,697,153, and $1,711,647, respectively.

In January 2006, the Company moved its primary operations into new facilities. The facility is subject to a lease which expires in 2018. Under the terms of the lease, the Company has options to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.

In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were accrued as a rent liability.

The future minimum lease payments under non-cancelable leases as of December 31, 2013 are as follows:


		Operating
Year		Lease
2014	$	1,593,756
2015		1,562,353
2016		1,930,829
2017		1,981,467
2018		2,008,832
Total minimum lease payments	$	9,077,237

Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Stockholders' Equity [Abstract]

Stockholders' Equity

11. Stockholders’ Equity

Listing Transfer to NASDAQ Capital Market

On August 15, 2013, the NASDAQ Listing Qualifications Panel (the “Panel”) granted approval of the Company’s request to transfer its listing to The NASDAQ Capital Market from The NASDAQ Global Market. The Company’s securities began trading on the NASDAQ Capital Market effective August 19, 2013.

Reverse Stock Split

On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”). The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock. The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the NASDAQ Global Market on a post-split basis on July 11, 2012.

As a result of the Reverse Stock Split, each ten shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Reverse Stock Split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock, restricted stock units, warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split reduced the number of shares of the Company’s common stock outstanding from approximately 78 million to 7.8 million at the time of the Reverse Stock Split. In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million. The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock. Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.

Public Offerings of Common Stock

In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 2.17 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $3.361 per share, together with six-year warrants at a price of $1.25 per share to purchase an aggregate of approximately 2.17 million shares of common stock having an exercise price of $3.361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased. Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses. The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.

On August 7, 2013, venture funds affiliated with Sanderling Ventures received an aggregate of 183,478 shares of common stock based upon the cashless exercise of warrants to purchase an aggregate of 262,450 shares of common stock. These warrants were comprised of 75,758 warrants with an exercise price of $1.98 per share, 156,204 warrants with an exercise price of $3.361 per share and 30,488 warrants with an exercise price of $4.10 per share. The warrants were issued by the Company in private placements in 2012 and 2013 in connection with the extension of previously disclosed guarantees.

On August 13, 2013, venture funds affiliated with Sanderling Ventures exercised PIPE Warrants to purchase an aggregate of 650,619 shares of common stock in a cashless net exercise as provided for in the PIPE Warrants, which resulted in the issuance to such funds of an aggregate of 308,194 shares of common stock. As a result, there were no net proceeds to the Company.

On August 16, 2013, certain affiliates of Franklin Templeton exercised PIPE Warrants to purchase an aggregate of 650,618 shares of common stock for cash. The Company received an aggregate of $2,186,727 gross proceeds from the sale.

On August 16, 2013, Alafi Capital Company exercised PIPE Warrants to purchase an aggregate of 261,241 shares of common stock for cash. The Company received an aggregate of $878,031 gross proceeds from the sale. Refer to Note 9 for the discussion of warrants issued in conjunction with debt offerings.

On November 27, 2013, the Company announced the results of its previously announced offering of subscription rights to purchase shares of its common stock, par value $0.001 per share. Pursuant to the rights offering, subscription rights to purchase approximately 3.4 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $10.2 million.

The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the our Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2013.

The Company has reserved shares of common stock for the exercise of warrants, the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:


	December 31,	December 31,
	2013	2012
Warrants	3,021,302	6,099,476
Stock award plans	1,032,462	131,464
	4,053,764	6,230,940

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.

The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.

Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.

Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of options to new directors generally vest over a two year period. Annual grants to directors generally vest upon the earlier of one year or the next stockholder meeting.

A summary of the option and stock appreciation rights activity for the year ended December 31, 2013 is as follows:


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90
Granted	-	$0.00 - $0.00	-
Exercised	(145)	$6.80 - $6.80	$ 6.80
Forfeited	(184,807)	$1.69 - $68.60	$ 39.34
Outstanding, December 31, 2013	188,947	$1.63 - $116.40	$ 48.38

As of December 31, 2013, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 3.88 years. Of the 188,947 options and stock appreciation rights that were outstanding as of December 31, 2013, 169,199 were vested and exercisable with a weighted average exercise price of $50.05 per share and a weighted average remaining term of 3.69 years.

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:


	Year Ended December 31, 2013
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $20.00		3,975		6.15 years	$	6.04		2,321	$	5.41
$20.01 - $40.00		92,356		5.32 years	$	35.13		77,390	$	35.08
$40.01 - $60.00		59,308		2.72 years	$	46.69		56,180	$	46.93
$60.01 - $90.00		13,408		0.85 years	$	74.04		13,408	$	74.04
$90.01 - $120.00		19,900		2.21 years	$	106.11		19,900	$	106.11
		188,947		3.88 years	$	48.38		169,199	$	50.05

The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the 1,625 options and stock appreciation rights that were in-the-money at December 31, 2013. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2013 and the intrinsic value of fully vested options and stock appreciation rights outstanding at December 31, 2013 were less than $0.1 million based on a closing share price of $3.62 on December 31, 2013. During the year ended December 31, 2013, the aggregate intrinsic value of options and stock appreciation rights exercised under the Company’s stock option plans was less than $0.1 million. No options or SARS were granted during the year ended December 31, 2013.

During the year ended December 31, 2013 the Company realized less than $0.1 million from the exercise of stock options and stock appreciation rights. The Company realized $0 and less than $0.1 million from the exercise of stock options and stock appreciation rights during 2012 and 2011, respectively.

A summary of the restricted share grant activity for the year ended December 31, 2013 is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2012	68,543	$ 20.62
Granted	-	-
Vested	(33)	$ 33.80
Forfeited	(61,910)	$ 19.06
Outstanding, December 31, 2013	6,600	$ 35.20

A summary of the restricted stock unit activity for the year ended December 31, 2013 is as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2012	529,312	$ 2.64
Granted	449,000	$ 2.20
Vested	(211,615)	$ 3.82
Forfeited	(177,938)	$ 2.09
Outstanding, December 31, 2013	588,759	$ 2.05

A summary of the restricted shares outstanding as of December 31, 2013 is as follows:


	Number of Shares

Time based restricted shares	6,600
Performance based restricted shares	-
Outstanding, December 31, 2013	6,600

The intrinsic value of restricted shares and restricted stock units outstanding at December 31, 2013 was less than $0.1 million and $2.1 million, respectively, based on a closing share price of $3.62 as of December 31, 2013. During the year ended December 31, 2013, the aggregate intrinsic value of restricted shares and restricted stock units vested was approximately $0 and $0.3 million, respectively, determined at the date of vesting.

During the year ended December 31, 2013, the Company determined that it was not probable that the performance conditions related to certain of its outstanding restricted share awards would be achieved and accordingly, recorded approximately $(0.2) million as a cumulative catch-up adjustment resulting in a reduction of share based compensation. During the second quarter of 2013, the Company made an adjustment to its forfeiture rate based on historical information, which resulted in a reduction of share-based compensation of $(0.5) million for the year ended December 31, 2013.

As of December 31, 2013, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.3 million, net of estimated forfeitures of approximately $1.2 million. This cost will be amortized over a period of up to four years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures.

2009 Employee Stock Purchase Plan

In 2009, the Company adopted its 2009 Employee Stock Purchase Plan and reserved 25,000 shares of common stock for issuance pursuant to the plan. The Company offered employees the opportunity to participate in the plan beginning July 1, 2009 with an initial purchase date of September 30, 2009. Eligible employees had the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees could purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. The plan was suspended in 2012 and no shares were available for issuance as of December 31, 2013.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2013

Fair Value Measurements [Abstract]

Fair Value Measurements

12. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2013:
Cash equivalents	$	11,995,481	11,995,481	—	—
Total assets at fair value	$	11,995,481	11,995,481	—	—
Liabilities at December 31, 2013:
Warrants issued December 29, 2008	$	16,863	—	—	16,863
Warrants issued May 10, 2012		1,915,753	—	—	1,915,753
Warrants issued August 2013		3,712,010			3,712,010
Total liabilities at fair value:	$	5,644,626	—	—	5,644,626
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $11,995,481 and $256,702 at December 31, 2013 and December 31, 2012, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the years ended December 31, 2013 and December 31, 2012. There were no transfers in or out of Level 1 during the year ended December 31, 2013.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 179,241 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.

In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $16,863 were measured at fair value on a recurring basis as of December 31, 2013 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at December 31, 2013 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 112.66%; 3) risk-free interest rate of 0.78%; and 4) expected life of 0.5 years.

In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants. The optional conversion feature of the subordinated convertible debentures is classified as a derivative liability within “Warrants and derivative liabilities” on the Company’s balance sheet. The warrants issued in conjunction with the Debentures and PIPE are also considered a liability. Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability were periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

Per the terms of the Debentures agreement, the Company had the ability to require each holder to convert up to 50% of the Debentures if the common stock closed above $15.00, or 100% of the Debentures if the common stock closed above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement had been declared effective by the SEC and was available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company could force the holders to convert was $2.5 million of Debentures in the aggregate. This mandatory redemption clause was classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset was periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

A Monte-Carlo simulation was used to value the derivative asset, liabilities and warrants upon issuance on May 10, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $3.413. Based on the discussion of the Debentures in Note 11, the Debentures along with their derivative liability and asset, and related warrants were extinguished in the third quarter of 2013.

The initial valuation of Exchange warrants were valued as of August 7, 2013 using the following assumptions: 1) volatility of 111%; 2) risk-free interest rate of 1.46%; and 3) a closing stock price of $8.69.

In accordance with general accounting principles for fair value measurement, the remaining PIPE and Exchange warrants were revalued as of December 31, 2013 using the following assumptions: 1) volatility of 142.28%; 2) risk-free interest rate of 1.75%; and 3) a closing stock price of $3.62.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) asset and liability fair value measurements.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the year ended December 31, 2013:


	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Derivative Liability	Total Liabilities
Balance at beginning of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902	$ -	$ 548,865	$ 2,968,348
Issues	-	-	-		19,358,108		19,358,108
Settlements	-	-	-	(18,780,167)	(10,535,592)	(12,828,650)	(42,144,409)
Revaluation	(1,736)	(1,736)	(54,718)	18,348,018	(5,110,506)	12,279,785	25,462,579
Balance at end of period	$ -	$ -	$ 16,863	$ 1,915,753	$ 3,712,010	$ -	$ 5,644,626

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Income Taxes

13. Income Taxes

The provision for income taxes consists of the following:


	Year Ended December 31,
	2013		2012		2011
Deferred:
Federal	$	(93,078,760)	$	4,586,506	$	11,367,771
State and local		(6,128,198)		493,946		1,437,062
		(99,206,958)		5,080,452		12,804,833
Valuation allowance		99,206,958		(5,080,452)		(12,804,833)
	$	—	$	—	$	—

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:


	Year Ended December 31,
	2013		2012		2011
U.S. statutory income tax rate	34.0	%	34	%	34	%
State and local taxes, net of federal tax benefit	(8.9)	%	5.2	%	4.5	%
Permanent differences between book and tax and other	(169.4)	%	14.4	%	1.5	%
Valuation allowance	144.3	%	(53.6)	%	(40)	%
Effective income tax rate	—	%	—	%	—	%

Included in permanent differences between book and tax and other in the above table are the impacts of the Section 382 limitation (discussed below) and the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment.

The components of the deferred tax asset are as follows:


	December 31,
	2013		2012
Current accruals	$	1,998,086	$	1,753,064
Depreciation and amortization		2,566,979		2,676,884
Deferred compensation		5,421,688		5,332,415
Net operating loss carryovers		28,045,831		127,477,179
Deferred tax assets		38,032,584		137,239,542
Valuation allowance		(38,032,584)		(137,239,542)
Net deferred tax assets	$	—	$	—

Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the “Code”, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to contributed capital.

Based on the results of the review, discussed above, as of December 31, 2013, we had federal net operating loss carryforwards of approximately $75.8 million. The federal net operating loss carryforwards will expire between 2018 and 2033. As of December 31, 2013, we had state net operating loss carryforwards of approximately $2.3 million which will expire at various dates between 2014 and 2032 if not utilized.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 1994 forward, all tax years from 1994 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.

The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2013 accrued interest and penalties were not material.

At December 31, 2013 and 2012, the Company had approximately $0.2 million in reserves for uncertain tax positions.

Net Loss Per Share

12 Months Ended

Dec. 31, 2013

Net loss per common share:

Net Loss Per Share

14. Net Loss per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:


	2013		2012		2011
Numerator:
Numerator for basic EPS	$	(68,757,589)	$	(9,238,427)	$	(32,031,175)
Effect of dilutive securities
Numerator for diluted EPS	$	(68,757,589)	$	(9,238,427)	$	(32,031,175)
Denominator:
Denominator for basic EPS—weighted average shares		11,554,566		6,944,928		5,482,627
Effect of dilutive securities
Denominator for diluted EPS		11,554,566		6,944,928		5,482,627
Basic EPS	$	(5.95)	$	(1.33)	$	(5.84)
Diluted EPS	$	(5.95)	$	(1.33)	$	(5.84)

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:


	December 31,
		2013	2012	2011
Shares outstanding
Restricted shares		6,600	68,543	52,659
Shares issuable upon vesting/exercise of:
Options to purchase common stock		188,947	373,899	562,733
Restricted stock units		588,759	529,312	98,820
Warrants		3,021,302	6,099,476	1,038,161
		3,805,608	7,071,230	1,752,373

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2013
Empoyee Benefit Plan [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan. Through September 30, 2011, the Company matched employee contributions dollar for dollar up to 3% of the employee’s salary during the employee’s period of participation. Such employer contributions are discretionary under the 401(k) plan. As of October 1, 2011, the Company suspended all matching contributions indefinitely. The Company had no expenses related to the employee contribution matching program for the year ended December 31, 2013. For the years ended December 31, 2012 and 2011, the Company expensed $8,595, and $395,633, respectively, related to the plan.

Product Warranty Provisions

12 Months Ended

Dec. 31, 2013

Product Warranty Provisions [Abstract]

Product Warranty Provisions

16. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe, Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	December 31, 2013		December 31, 2012
Warranty accrual, beginning of the fiscal period	$	653,473	$	691,832
Warranty expense incurred		84,562		650,367
Payments made		(236,823)		(688,726)
Warranty accrual, end of the fiscal period	$	501,212	$	653,473

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2013
Commitments And Contingencies [Abstract]
Commitments And Contingencies	17. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. In 2012, the Company entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015.

Segment Information

12 Months Ended

Dec. 31, 2013

Segment Information [Abstract]

Segment Information

18. Segment Information

The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment.


	Year Ended December 31,
	2013		2012		2011
United States	$	24,063,932	$	27,034,200	$	23,947,048
International		13,967,149		19,528,234		18,040,384
Total	$	38,031,081	$	46,562,434	$	41,987,432

All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Quarterly Data (Unaudited)

12 Months Ended

Dec. 31, 2013

Quarterly Data (Unaudited) [Abstract]

Quarterly Data (Unaudited)

19. Quarterly Data (Unaudited)

The following tabulations reflect the unaudited quarterly results of operations for the years ended December 31, 2013 and 2012:



							Basic Net		Diluted Net
					Net Income		Income (Loss)		Income (Loss)
	Net Sales		Gross Profit		(Loss)		Per Share		Per Share
2013
First quarter	$	8,408,204	$	6,215,559	$	(4,920,147)	$	(0.61)	$	(0.61)
Second quarter		9,733,407		7,261,519		(3,006,792)		(0.37)		(0.37)
Third quarter		10,821,444		7,321,820		(56,868,442)		(4.49)		(4.49)
Fourth quarter		9,068,026		6,230,882		(3,962,208)		(0.23)		(0.23)
2012
First quarter	$	12,283,228	$	8,521,397	$	(5,812,912)	$	(1.06)	$	(1.06)
Second quarter		10,512,898		7,252,820		2,806,427		0.42		0.32
Third quarter		11,561,399		8,074,578		(1,915,281)		(0.25)		(0.25)
Fourth quarter		12,204,909		7,932,584		(4,316,661)		(0.55)		(0.55)

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events None.

Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2013

Valuation And Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2013, 2012, AND 2011


			Additions
	Balance at		Charged to
	Beginning of		Cost and				Balance at the
	Year		Expenses		Deductions		End of Year
Allowance for doubtful accounts and returns:
Year ended December 31, 2013	$	640,183	$	65,781	$	(322,887)	$	383,077
Year ended December 31, 2012	$	667,529	$	763	$	(28,109)	$	640,183
Year ended December 31, 2011	$	367,536	$	691,459	$	(391,466)	$	667,529

Allowance for inventories valuation:
Year ended December 31, 2013	$	72,639	$	179,803	$	(172,229)	$	80,213
Year ended December 31, 2012	$	151,157	$	122,783	$	(201,301)	$	72,639
Year ended December 31, 2011	$	539,518	$	156,852	$	(545,213)	$	151,157

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
Summary Of Significant Accounting Policies (Policy)	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. In 2012, we entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015. No cash was restricted at December 31, 2013 or 2012.
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property and Equipment	Property and Equipment Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research and Development	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2013 or 2012 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments.
Net Loss Per Common Share	Net Loss per Common Share Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2013, 2012, and 2011 are presented on a post-split basis. See Note 11 for additional discussion of the reverse stock split. As of December 31, 2013, the Company had 188,947 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $48.38 per share and 3,021,302 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $14.21 per share. The Company had a weighted average of 33,058 unearned restricted shares outstanding for the period ended December 31, 2013.
Income Tax	Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. One customer, Biosense Webster Inc., as our distributor, accounted for $3,902,178, $3,447,386, and $3,663,687, or 10%, 7% and 9%, of total net revenue for the years ended December 31, 2013, 2012, and 2011, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2013.
Reclassifications	Reclassifications Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split.

Inventory (Tables)

12 Months Ended

Dec. 31, 2013

Inventory [Abstract]

Schedule Of Inventory


	December 31, 2013	December 31, 2012

Raw materials	$ 3,141,111	$ 3,303,053
Work in process	364,779	65,546
Finished goods	1,453,362	1,802,281
Reserve for obsolescence	(80,213)	(72,639)
Total inventory	$ 4,879,039	$ 5,098,241

Prepaid Expenses And Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2013

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets



	December 31, 2013	December 31, 2012

Prepaid expenses	$ 591,305	$ 330,756
Deferred cost of revenue	72,699	527,725
Derivative asset	—	1,736
Deferred financing costs	622,949	1,590,916
Deposits	658,253	1,040,934
Total prepaid expenses and other current assets	$ 1,945,206	$ 3,492,067

Property And Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	December 31,	December 31,
	2013	2012

Equipment	$ 8,143,000	$ 8,762,041
Equipment held for lease	303,412	303,412
Leasehold improvements	2,328,381	2,328,381
	10,774,793	11,393,834
Less: Accumulated depreciation	(9,590,204)	(9,251,911)
Net property and equipment	$ 1,184,589	$ 2,141,923

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2013

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	December 31,	December 31,
	2013	2012

Accrued salaries, bonus, and benefits	$ 3,565,385	$ 2,123,167
Accrued rent	1,499,942	1,095,641
Accrued warranties	501,212	653,473
Accrued interest	498,058	469,049
Accrued licenses and maintenance fees	302,384	323,901
Accrued taxes	360,475	245,802
Other	351,925	450,777
Total accrued liabilities	$ 7,079,381	$ 5,361,810

Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2013

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	December 31,	December 31,
	2013	2012

Product shipped, revenue deferred	$ 1,368,007	$ 3,206,641
Customer deposits	421,544	558,227
Deferred service and license fees	6,221,283	6,215,230
	8,010,834	9,980,098
Less: Long-term deferred revenue	(491,080)	(477,159)
Total current deferred revenue	$ 7,519,754	$ 9,502,939

Long-Term Debt And Credit Facilities (Tables)

12 Months Ended

Dec. 31, 2013

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Long-Term Debt Outstanding


	December 31, 2013		December 31, 2012
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due March 2014	$ -	$ -	$ 7,253,017	$ 7,277,084
Term note, due December 2013	—	—	4,000,000	4,000,000
Healthcare Royalty Partners debt	18,531,211	18,531,211	16,248,075	16,248,075
Subordinated convertible debentures	—	—	1,588,134	1,588,134
Total debt	18,531,211	18,531,211	29,089,226	29,113,293
Less current maturities	(49,733)	(49,733)	(12,264,490)	(12,288,557)
Total long term debt	$ 18,481,478	$ 18,481,478	$ 16,824,736	$ 16,824,736

Contractual Principal Maturities Of Debt



2014	$	49,733
2015		49,733
2016		49,733
2017		49,733
2018		18,332,279
2019 and Beyond		-
	$	18,531,211	(1)


(1) Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2013

Lease Obligations [Abstract]

Schedule Of Future Minimum Lease Payments


		Operating
Year		Lease
2014	$	1,593,756
2015		1,562,353
2016		1,930,829
2017		1,981,467
2018		2,008,832
Total minimum lease payments	$	9,077,237

Stockholder's Equity (Tables)

12 Months Ended

Dec. 31, 2013

Stockholders' Equity [Abstract]

Summary Of Reserved Shares Of Common Stock


	December 31,	December 31,
	2013	2012
Warrants	3,021,302	6,099,476
Stock award plans	1,032,462	131,464
	4,053,764	6,230,940

Summary Of The Option And Stock Appreciation Rights Activity


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90
Granted	-	$0.00 - $0.00	-
Exercised	(145)	$6.80 - $6.80	$ 6.80
Forfeited	(184,807)	$1.69 - $68.60	$ 39.34
Outstanding, December 31, 2013	188,947	$1.63 - $116.40	$ 48.38

Summary Of The Options And Stock Appreciation Rights Outstanding By Range Of Excercise Price


	Year Ended December 31, 2013
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $20.00		3,975		6.15 years	$	6.04		2,321	$	5.41
$20.01 - $40.00		92,356		5.32 years	$	35.13		77,390	$	35.08
$40.01 - $60.00		59,308		2.72 years	$	46.69		56,180	$	46.93
$60.01 - $90.00		13,408		0.85 years	$	74.04		13,408	$	74.04
$90.01 - $120.00		19,900		2.21 years	$	106.11		19,900	$	106.11
		188,947		3.88 years	$	48.38		169,199	$	50.05

Summary Of The Restricted Share Grant Activity


	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2012	68,543	$ 20.62
Granted	-	-
Vested	(33)	$ 33.80
Forfeited	(61,910)	$ 19.06
Outstanding, December 31, 2013	6,600	$ 35.20

Summary Of The Restricted Stock Unit Activity


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2012	529,312	$ 2.64
Granted	449,000	$ 2.20
Vested	(211,615)	$ 3.82
Forfeited	(177,938)	$ 2.09
Outstanding, December 31, 2013	588,759	$ 2.05

Summary Of The Restricted Shares Outstanding


	Number of Shares

Time based restricted shares	6,600
Performance based restricted shares	-
Outstanding, December 31, 2013	6,600

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2013

Fair Value Measurements [Abstract]

Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2013:
Cash equivalents	$	11,995,481	11,995,481	—	—
Total assets at fair value	$	11,995,481	11,995,481	—	—
Liabilities at December 31, 2013:
Warrants issued December 29, 2008	$	16,863	—	—	16,863
Warrants issued May 10, 2012		1,915,753	—	—	1,915,753
Warrants issued August 2013		3,712,010			3,712,010
Total liabilities at fair value:	$	5,644,626	—	—	5,644,626
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348

Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities


	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Derivative Liability	Total Liabilities
Balance at beginning of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902	$ -	$ 548,865	$ 2,968,348
Issues	-	-	-		19,358,108		19,358,108
Settlements	-	-	-	(18,780,167)	(10,535,592)	(12,828,650)	(42,144,409)
Revaluation	(1,736)	(1,736)	(54,718)	18,348,018	(5,110,506)	12,279,785	25,462,579
Balance at end of period	$ -	$ -	$ 16,863	$ 1,915,753	$ 3,712,010	$ -	$ 5,644,626

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Schedule of Components of Income Tax Provision


	Year Ended December 31,
	2013		2012		2011
Deferred:
Federal	$	(93,078,760)	$	4,586,506	$	11,367,771
State and local		(6,128,198)		493,946		1,437,062
		(99,206,958)		5,080,452		12,804,833
Valuation allowance		99,206,958		(5,080,452)		(12,804,833)
	$	—	$	—	$	—

Schedule of Reconciliation of Federal Income Tax Rate


	Year Ended December 31,
	2013		2012		2011
U.S. statutory income tax rate	34.0	%	34	%	34	%
State and local taxes, net of federal tax benefit	(8.9)	%	5.2	%	4.5	%
Permanent differences between book and tax and other	(169.4)	%	14.4	%	1.5	%
Valuation allowance	144.3	%	(53.6)	%	(40)	%
Effective income tax rate	—	%	—	%	—	%

Schedule of Deferred Tax Assets


	December 31,
	2013		2012
Current accruals	$	1,998,086	$	1,753,064
Depreciation and amortization		2,566,979		2,676,884
Deferred compensation		5,421,688		5,332,415
Net operating loss carryovers		28,045,831		127,477,179
Deferred tax assets		38,032,584		137,239,542
Valuation allowance		(38,032,584)		(137,239,542)
Net deferred tax assets	$	—	$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2013

Net loss per common share:

Computation Of Basic And Diluted EPS


	2013		2012		2011
Numerator:
Numerator for basic EPS	$	(68,757,589)	$	(9,238,427)	$	(32,031,175)
Effect of dilutive securities
Numerator for diluted EPS	$	(68,757,589)	$	(9,238,427)	$	(32,031,175)
Denominator:
Denominator for basic EPS—weighted average shares		11,554,566		6,944,928		5,482,627
Effect of dilutive securities
Denominator for diluted EPS		11,554,566		6,944,928		5,482,627
Basic EPS	$	(5.95)	$	(1.33)	$	(5.84)
Diluted EPS	$	(5.95)	$	(1.33)	$	(5.84)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	December 31,
		2013	2012	2011
Shares outstanding
Restricted shares		6,600	68,543	52,659
Shares issuable upon vesting/exercise of:
Options to purchase common stock		188,947	373,899	562,733
Restricted stock units		588,759	529,312	98,820
Warrants		3,021,302	6,099,476	1,038,161
		3,805,608	7,071,230	1,752,373

Product Warranty Provisions (Tables)

12 Months Ended

Dec. 31, 2013

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	December 31, 2013		December 31, 2012
Warranty accrual, beginning of the fiscal period	$	653,473	$	691,832
Warranty expense incurred		84,562		650,367
Payments made		(236,823)		(688,726)
Warranty accrual, end of the fiscal period	$	501,212	$	653,473

Segment Information (Tables)

12 Months Ended

Dec. 31, 2013

Segment Information [Abstract]

Schedule of Revenue by Geographical Areas


	Year Ended December 31,
	2013		2012		2011
United States	$	24,063,932	$	27,034,200	$	23,947,048
International		13,967,149		19,528,234		18,040,384
Total	$	38,031,081	$	46,562,434	$	41,987,432

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly Data (Unaudited) [Abstract]

Schedule of Quarterly Financial Information



							Basic Net		Diluted Net
					Net Income		Income (Loss)		Income (Loss)
	Net Sales		Gross Profit		(Loss)		Per Share		Per Share
2013
First quarter	$	8,408,204	$	6,215,559	$	(4,920,147)	$	(0.61)	$	(0.61)
Second quarter		9,733,407		7,261,519		(3,006,792)		(0.37)		(0.37)
Third quarter		10,821,444		7,321,820		(56,868,442)		(4.49)		(4.49)
Fourth quarter		9,068,026		6,230,882		(3,962,208)		(0.23)		(0.23)
2012
First quarter	$	12,283,228	$	8,521,397	$	(5,812,912)	$	(1.06)	$	(1.06)
Second quarter		10,512,898		7,252,820		2,806,427		0.42		0.32
Third quarter		11,561,399		8,074,578		(1,915,281)		(0.25)		(0.25)
Fourth quarter		12,204,909		7,932,584		(4,316,661)		(0.55)		(0.55)

Description Of Business (Details)	12 Months Ended
Description Of Business (Details)	Dec. 31, 2013 USD ($) item	Dec. 31, 2012 USD ($)
Description Of Business [Line Items]
Cumulative losses incurred from inception \| $	$ (453,403,462)	$ (384,645,873)
Installed base \| item	100
Scenario, Forecast [Member] \| Maximum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	20.00%
Scenario, Forecast [Member] \| Minimum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	15.00%

Summary Of Significant Accounting Policies (Narrative) (Details)			3 Months Ended								12 Months Ended
	Jul. 10, 2012	Jul. 10, 2012	Dec. 31, 2013 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2012 USD ($) $ / shares shares	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Restricted cash			$ 0				$ 0				$ 0	$ 0
Reverse stock split		0.1
Stock options and stock appreciation rights \| shares			188,947				373,899				188,947	373,899
Weighted average exercise price \| $ / shares			$ 48.38				$ 43.90				$ 48.38	$ 43.90
Common stock issuable upon exercise of outstanding warrants \| shares			3,021,302				6,099,476				3,021,302	6,099,476
Weighted average exercise price of warrants or rights \| $ / shares			$ 14.21								$ 14.21
Revenues			$ 9,068,026	$ 10,821,444	$ 9,733,407	$ 8,408,204	$ 12,204,909	$ 11,561,399	$ 10,512,898	$ 12,283,228	$ 38,031,081	$ 46,562,434	$ 41,987,432
Research and development receivable			$ 0				0				$ 0	0
Restricted Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Weighted average unearned restricted shares outstanding \| shares											33,058
Biosense Webster Inc. [Member] \| Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenues											$ 3,902,178	$ 3,447,386	$ 3,663,687
Major customer, revenue percentage											10.00%	7.00%	9.00%
Letter of Credit [Member]
Summary Of Significant Accounting Policies [Line Items]
Maximum borrowing capacity							$ 100,000					$ 100,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life											3 years
Intangible assets, useful life											10 years
Reverse stock split	0.25
Share based compensation, requisite service period											1 year
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life											10 years
Intangible assets, useful life											15 years
Reverse stock split	0.10
Share based compensation, requisite service period											4 years

Inventory (Schedule Of Inventory) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Abstract]
Raw materials	$ 3,141,111	$ 3,303,053
Work in process	364,779	65,546
Finished goods	1,453,362	1,802,281
Reserve for obsolescence	(80,213)	(72,639)
Total inventory	$ 4,879,039	$ 5,098,241

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 591,305	$ 330,756
Deferred cost of revenue	72,699	527,725
Derivative asset		1,736
Deferred financing costs	622,949	1,590,916
Deposits	658,253	1,040,934
Total prepaid expenses and other current assets	$ 1,945,206	$ 3,492,067

Property And Equipment (Schedule Of Property And Equipment) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 10,774,793	$ 11,393,834
Less: Accumulated depreciation	(9,590,204)	(9,251,911)
Net property and equipment	1,184,589	2,141,923
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,143,000	8,762,041
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,328,381	$ 2,328,381

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible Assets [Abstract]
Total intangible assets, including those subject to execution of agreement	$ 3,665,000	$ 3,665,000
Accumulated amortization	1,985,514	1,685,680
Amortization Expense	299,833	$ 299,833	$ 299,833
Future Amortization Expense, Through July 2018	299,833
Future Amortization Expense, August 2018 Through May 2020	$ 166,500

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 3,565,385	$ 2,123,167
Accrued rent	1,499,942	1,095,641
Accrued warranties	501,212	653,473	$ 691,832
Accrued interest	498,058	469,049
Accrued license and maintenance fees	302,384	323,901
Accrued taxes	360,475	245,802
Other	351,925	450,777
Total accrued liabilities	$ 7,079,381	$ 5,361,810

Deferred Revenue (Schedule Of Deferred Revenue) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 8,010,834	$ 9,980,098
Less: Long-term deferred revenue	(491,080)	(477,159)
Total current deferred revenue	7,519,754	9,502,939
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	1,368,007	3,206,641
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	421,544	558,227
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 6,221,283	$ 6,215,230

Long-Term Debt And Credit Facilities (Narrative) (Details) $ / shares in Units, item in Millions		1 Months Ended					3 Months Ended		12 Months Ended
	Aug. 07, 2013 USD ($) $ / shares shares	Jan. 31, 2013 USD ($)	May 31, 2012 USD ($) item $ / shares shares	Nov. 30, 2011 USD ($)	Dec. 31, 2010 USD ($) $ / shares shares	Jul. 31, 2008 USD ($)	Dec. 31, 2013 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) shares	Dec. 31, 2011 USD ($)	Aug. 08, 2013 shares
Debt Instrument [Line Items]
Warrants \| shares							3,021,302		3,021,302	6,099,476
Number of shares issued upon conversion of warrants \| shares	262,450
Paydown of the guarantees									$ 7,000,000
Amount borrowed									2,546,328	$ 2,500,000	$ 14,317,397
Write-off of unamortized discount									5,400,000
Convert Warrants [Member]
Debt Instrument [Line Items]
Aggregate number of shares issued upon conversion \| shares	2,500,000
Proceeds from the exercise of stock warrants	$ 8,500,000
Exchange Warrants [Member]
Debt Instrument [Line Items]
Number of shares issued upon conversion of warrants \| shares												1,400,000
Aggregate number of shares issued upon conversion \| shares												800,000
Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Current borrowing capacity							$ 3,000,000		3,000,000
Line of credit, current availability							3,000,000		3,000,000
Line of credit facility, amount outstanding							0		0
Term Note [Member]
Debt Instrument [Line Items]
Warrants \| shares					11,111
Exercise price of warrants \| $ / shares					$ 36.00
Fair value of warrants issued					$ 228,332
Term loan agreement, face value					10,000,000
Healthcare Royalty Partners debt [Member]
Debt Instrument [Line Items]
Amount borrowed				$ 15,000,000
Additional amount which may be borrowed				$ 5,000,000
Percentage of royalties entitled to				100.00%
Annual interest rate				16.00%
Additional amount borrowed		$ 2,500,000							2,500,000
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Warrants \| shares			2,500,000
Exercise price of warrants \| $ / shares			$ 3.361
Annual interest rate			8.00%
Proceeds from Convertible Debt			$ 8,500,000
Conversion price per share \| $ / shares			$ 3.361
Number of convertible shares \| item			2.5
Debt discount			$ 7,600,000
Fair value of warrants			4,100,000
Fair value of derivative liability			$ 3,500,000
Unconverted Debentures [Member]
Debt Instrument [Line Items]
Number of shares issued upon conversion of warrants \| shares	2,500,000
Aggregate number of shares issued upon conversion \| shares	2,700,000
Exercise price of warrants \| $ / shares	$ 3.361
Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts						$ 18,000,000
Research and development expenses, Biosense Webster											1,100,000
Disposables, service and accessories revenue, Biosense Webster											$ 3,600,000
2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							30,000,000		$ 30,000,000
Accrued interest on facility, floor									7.00%
2009 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees From Stockholders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							10,000,000		$ 10,000,000
Accrued interest on facility, floor									6.00%
November 2010 Agreement [Member] \| Revolving Line Of Credit [Member] \| Guarantees From Stockholders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 10,000,000		$ 10,000,000
Debt maturity date									Mar. 31, 2012
Warrants \| shares							80,000		80,000
Exercise price of warrants \| $ / shares							$ 40.15		$ 40.15
Fair value of warrants issued							$ 1,747,392		$ 1,747,392
March 30, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Debt maturity date									Apr. 30, 2012
Decrease in maximum borrowing capacity									$ 3,333,333
March 30, 2012 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 10,000,000		$ 10,000,000
Debt maturity date									Apr. 30, 2012
Number of shares issued upon conversion of warrants \| shares							75,735		75,735
Exercise price of warrants \| $ / shares							$ 6.60		$ 6.60
May 1, 2012 Agreement [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Debt maturity date									May 15, 2012
May 1, 2012 Agreement [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 10,000,000		$ 10,000,000
Debt maturity date									May 15, 2012
Number of shares issued upon conversion of warrants \| shares							60,976		60,976
Exercise price of warrants \| $ / shares							$ 4.10		$ 4.10
May 10, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 13,000,000		$ 13,000,000
Debt maturity date									Mar. 31, 2013
May 10, 2012 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 3,000,000		$ 3,000,000
Debt maturity date									Mar. 31, 2013
Number of shares issued upon conversion of warrants \| shares							234,305		234,305
Exercise price of warrants \| $ / shares							$ 3.361		$ 3.361
Paydown of the guarantees									$ 7,000,000
May 10, 2012 Amendment [Member] \| Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt									$ 18,500,000
March 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Debt maturity date									Jun. 30, 2013
March 2013 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 3,000,000		$ 3,000,000
Debt maturity date									Jun. 30, 2013
Number of shares issued upon conversion of warrants \| shares							113,636		113,636
Exercise price of warrants \| $ / shares							$ 1.98		$ 1.98
June 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 6,000,000		$ 6,000,000
Debt maturity date									Jul. 31, 2013
June 2013 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 3,000,000		$ 3,000,000
Debt maturity date									Jul. 31, 2013
Number of shares issued upon conversion of warrants \| shares							48,387		48,387
Exercise price of warrants \| $ / shares							$ 1.55		$ 1.55
July 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Debt maturity date									Aug. 31, 2013
July 2013 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 3,000,000		$ 3,000,000
Debt maturity date									Aug. 31, 2013
Number of shares issued upon conversion of warrants \| shares							14,313		14,313
Exercise price of warrants \| $ / shares							$ 5.24		$ 5.24
August 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 3,000,000		$ 3,000,000
Debt maturity date									Mar. 31, 2014
Earnings before interest and depreciation and amortization revolving credit convenant							$ (3,000,000)	$ (4,000,000)
Liquidity ratio							2		2
August 2013 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees Provided By Lenders [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 0		$ 0
September 2011 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 20,000,000		$ 20,000,000
September 2011 Amendment [Member] \| Term Note [Member] \| Lender's Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate									3.50%
September 2011 Amendment [Member] \| Term Note [Member] \| Bank's Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate									5.50%
Principal Due 2013 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					4,000,000
Principal Due 2012 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					4,000,000
Principal Due 2011 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due					$ 2,000,000
Research And Development Expenses [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts						8,000,000
Royalty Amounts [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts						$ 10,000,000
Prime Rate Plus [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate						0.75%
Prime Rate Plus [Member] \| 2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate									1.75%
Prime Rate Plus [Member] \| 2009 Amendment [Member] \| Revolving Line Of Credit [Member] \| Guarantees From Stockholders [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate									0.50%
Prime Rate Plus [Member] \| 2010 Amendment To Loan Agreement [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate					3.50%

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) - USD ($)

Dec. 31, 2013

Dec. 31, 2012

Debt Instrument [Line Items]

Total debt, Carrying Amount

$ 18,531,211

^[1]

$ 29,089,226

Less current maturities, Carrying Amount

(49,733)

(12,264,490)

Total long term debt, Carrying Amount

18,481,478

16,824,736

Total debt, Estimated Fair Value

18,531,211

29,113,293

Less current maturities, Estimated Fair Value

(49,733)

(12,288,557)

Total long term debt, Estimated Fair Value

18,481,478

16,824,736

Revolving Credit Agreement Due March 2014 [Member]

Debt Instrument [Line Items]

Total debt, Carrying Amount

7,253,017

Total debt, Estimated Fair Value

7,277,084

Term Note, Due December 2013 [Member]

Debt Instrument [Line Items]

Total debt, Carrying Amount

4,000,000

Total debt, Estimated Fair Value

4,000,000

Healthcare Royalty Partners debt [Member]

Debt Instrument [Line Items]

Total debt, Carrying Amount

18,531,211

16,248,075

Total debt, Estimated Fair Value

$ 18,531,211

16,248,075

Subordinated Convertible Debentures [Member]

Debt Instrument [Line Items]

Total debt, Carrying Amount

1,588,134

Total debt, Estimated Fair Value

$ 1,588,134

[1]	Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

Long-Term Debt And Credit Facilities (Contractual Principal Maturities Of Debt) (Details) - USD ($)

Dec. 31, 2013

Dec. 31, 2012

Maturities of Long-term Debt [Abstract]

2014

$ 49,733

$ 12,264,490

49,733

49,733

49,733

18,332,279

Total debt, Carrying Amount

$ 18,531,211

^[1]

$ 29,089,226

[1]	Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

Lease Obligations (Narrative) (Details)	3 Months Ended	12 Months Ended
Lease Obligations (Narrative) (Details)	Sep. 30, 2013 ft²	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Lease Obligations [Abstract]
Rent Expense \| $		$ 1,925,813	$ 1,697,153	$ 1,711,647
Lease renewal term		3 years
Area of leased space, terminated \| ft²	13,000

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2013 USD ($)
Lease Obligations [Abstract]
2014	$ 1,593,756
2015	1,562,353
2016	1,930,829
2017	1,981,467
2018	2,008,832
Total minimum lease payments	$ 9,077,237

Stockholders' Equity (Narrative) (Details)					1 Months Ended			12 Months Ended
Stockholders' Equity (Narrative) (Details)	Aug. 13, 2013 USD ($) shares	Aug. 07, 2013 $ / shares shares	Jul. 10, 2012 shares	Jul. 10, 2012 shares	Nov. 27, 2013 USD ($) shares	Aug. 16, 2013 USD ($) shares	May 31, 2012 $ / shares $ / item shares	Dec. 31, 2013 USD ($) $ / shares item shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($)	Dec. 31, 2009 USD ($)	Jul. 09, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued, value \| $								$ 64,594,513	$ 10,411,675
Reverse stock split				0.1
Common stock authorized								300,000,000	300,000,000			100,000,000
Common stock authorized due to Amendment			300,000,000	300,000,000
Common stock par value \| $ / shares								$ 0.001	$ 0.001
Net proceeds from sale of securities \| $								$ 9,100,000
Paydown of the guarantees \| $								$ 7,000,000
Number of shares issued upon conversion of warrants		183,478
Aggregate number of shares issued upon conversion of subscription rights		262,450
Votes per share \| item								1
Dividends declared \| $								$ 0
Dividends paid \| $								0
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees \| $								1,300,000
Estimated forfeitures \| $								$ 1,200,000
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years								4 years
Options To Purchase Common Stock								188,947	373,899
Weighted average remaining life								3 years 10 months 17 days
Weighted average exercise price per vested share \| $ / shares								$ 50.05
Number of options currently exercisable								169,199
Weighted average remaining life of vested options outstanding								3 years 8 months 9 days
Options and stock appreciation rights in-the-money								1,625
Closing stock price \| $ / shares								$ 3.62
Grants in period								0
Proceeds from options exercised \| $									$ 0
Intrinsic value of restricted shares outstanding \| $								$ 100,000
Intrinsic value of restricted stock units outstanding \| $								2,100,000
Intrinsic value of vested restricted shares \| $								0
Intrinsic value of vested restricted stock units \| $								300,000
Adjustment for unmet performance conditions \| $								(200,000)
Adjustment for forfiture rate, \| $								$ (500,000)
Shares authorized under plan								25,000
Percentage of compensation eligible employees can use to purchase common stock, maximum											15.00%
Compensation amount eligible employees can use to purcahse common stock, maximum \| $											$ 25,000
Percentage of fair value eligible employees can purchase common stock											95.00%
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, expiration term								10 years
Exercise price as percentage of fair value								100.00%
2009 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available under ESPP								0
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, expiration term								10 years
Exercise price as percentage of fair value								100.00%
Initial Grant [Member] \| Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period								2 years
Annual Grants [Member] \| Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period								1 year
Incentive Stock Options [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period								3 years
Incentive Stock Options [Member] \| First Anniversary [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting, percentage								25.00%
Incentive Stock Options [Member] \| Subsequent Monthly Vesting [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting, percentage								0.0208%
Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period								0
Stock Appreciation Rights (SARs) [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, expiration term								10 years
Option vesting period								3 years
Stock Appreciation Rights (SARs) [Member] \| First Anniversary [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting, percentage								25.00%
Time Based Restricted Shares [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period								3 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period								4 years
Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued, shares					3,400,000
Stock issued, value \| $					$ 10,200,000
Pre-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding			78,000,000	78,000,000
Post-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding			7,800,000	7,800,000
Shares sold in private placement							2,170,000
Share price of shares sold in private placement \| $ / item							3.361
Warrants sold in private placement							2,170,000
Duration period of warrants								6 years
Share price of warrants sold in private placement \| $ / shares							$ 1.25
Exercise price of warrants \| $ / shares							$ 3.361
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split			0.25
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split			0.10
Intrinsic value of options and stock appreciation rights outstanding \| $								$ 100,000
Intrinsic value of options and stock appreciation rights exercised \| $								100,000
Proceeds from options exercised \| $								$ 100,000		$ 100,000
Warrrant Exercise Price $1.98 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / shares		$ 1.98
Aggregate number of shares issued upon conversion of subscription rights		75,758
Warrrant Exercise Price $3.361 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / shares		$ 3.361
Aggregate number of shares issued upon conversion of subscription rights		156,204
Warrrant Exercise Price $4.10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / shares		$ 4.10
Aggregate number of shares issued upon conversion of subscription rights		30,488
Sanderling Ventures PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued upon conversion of warrants	308,194
Aggregate number of shares issued upon conversion of subscription rights	650,619
Proceeds from the exercise of stock warrants \| $	$ 0
Franklin Templeton PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares issued upon conversion of subscription rights						650,618
Proceeds from the exercise of stock warrants \| $						$ 2,186,727
Alafi Capital Company PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares issued upon conversion of subscription rights						261,241
Proceeds from the exercise of stock warrants \| $						$ 878,031

Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details) - shares	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Abstract]
Warrants	3,021,302	6,099,476
Stock award plans	1,032,462	131,464
Total Reserved Shares of Common Stock	4,053,764	6,230,940

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2012	373,899
Number of Options/SARs, Exercised	(145)
Number of Options/SARs, Forfeited	(184,807)
Number of Options/SARs, Outstanding, December 31, 2013	188,947	373,899
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 43.90
Weighted Average Exercise Price per Share, Exercised	6.80
Weighted Average Exercise Price per Share, Forfeited	39.34
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	48.38	$ 43.90
Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice	1.63	1.63
Range of Exercise Price, Granted	0.00
Range of Exercise Price, Exercised	6.80
Range of Exercise Price, Forfeited	1.69
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice	1.63	1.63
Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice	116.40	116.40
Range of Exercise Price, Granted	0.00
Range of Exercise Price, Exercised	6.80
Range of Exercise Price, Forfeited	68.60
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice	$ 116.40	$ 116.40

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Outstanding) (Details)	12 Months Ended
	Dec. 31, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	188,947
Weighted average remaining life	3 years 10 months 17 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 48.38
Number of options currently exercisable \| shares	169,199
Weighted average exercise price per vested share	$ 50.05
$0.00 - $20.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower limit	0.00
Range of Exercise Price, Upper limit	$ 20.00
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	3,975
Weighted average remaining life	6 years 1 month 24 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 6.04
Number of options currently exercisable \| shares	2,321
Weighted average exercise price per vested share	$ 5.41
$20.01 - $40.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower limit	20.01
Range of Exercise Price, Upper limit	$ 40.00
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	92,356
Weighted average remaining life	5 years 3 months 26 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 35.13
Number of options currently exercisable \| shares	77,390
Weighted average exercise price per vested share	$ 35.08
$40.01 - $60.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower limit	40.01
Range of Exercise Price, Upper limit	$ 60.00
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	59,308
Weighted average remaining life	2 years 8 months 19 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 46.69
Number of options currently exercisable \| shares	56,180
Weighted average exercise price per vested share	$ 46.93
$60.01 - $90.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower limit	60.01
Range of Exercise Price, Upper limit	$ 90.00
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	13,408
Weighted average remaining life	10 months 6 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 74.04
Number of options currently exercisable \| shares	13,408
Weighted average exercise price per vested share	$ 74.04
$90.01 - $120.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower limit	90.01
Range of Exercise Price, Upper limit	$ 120.00
Number of Options/SARs, Outstanding, December 31, 2013 \| shares	19,900
Weighted average remaining life	2 years 2 months 16 days
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$ 106.11
Number of options currently exercisable \| shares	19,900
Weighted average exercise price per vested share	$ 106.11

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) - Restricted Shares [Member]	12 Months Ended
	Dec. 31, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2012 \| shares	68,543
Number of Shares, Granted \| shares
Number of Shares, Vested \| shares	(33)
Number of Shares, Forfeited \| shares	(61,910)
Number of Shares, Outstanding, December 31, 2013 \| shares	6,600
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 20.62
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	33.80
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	19.06
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013 \| $ / shares	$ 35.20

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2012 \| shares	529,312
Number of Shares, Granted \| shares	449,000
Number of Shares, Vested \| shares	(211,615)
Number of Shares, Forfeited \| shares	(177,938)
Number of Shares, Outstanding, December 31, 2013 \| shares	588,759
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 2.64
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	2.20
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	3.82
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	2.09
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013 \| $ / shares	$ 2.05

Stockholders' Equity (Summary Of The Restricted Shares Outstanding) (Details) - Restricted Shares [Member] - shares	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	6,600	68,543
Time Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	6,600

Fair Value Measurements (Narrative) (Details)			12 Months Ended
Fair Value Measurements (Narrative) (Details)	Aug. 07, 2013 $ / shares	May 10, 2012 $ / shares	Dec. 31, 2013 USD ($) $ / shares shares	Aug. 31, 2013 USD ($) $ / item	Dec. 31, 2012 USD ($) shares	Dec. 29, 2008 shares
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds			$ 11,995,481		$ 256,702
Issued warrants to purchase shares of common stock \| shares			3,021,302		6,099,476
Closing stock price \| $ / shares			$ 3.62
Common Stock Closes Above $15.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement				50.00%
Share price which determines conversion per Debentures agreement \| $ / item				15.00
Number of consecutive trading days required at stock price			20 days
Mandatory conversion minimum per Debentures agreement				$ 2,500,000
Common Stock Closes Above $20.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement				100.00%
Share price which determines conversion per Debentures agreement \| $ / item				20.00
Number of consecutive trading days required at stock price			20 days
Mandatory conversion minimum per Debentures agreement				$ 2,500,000
Black-Scholes Model Used to Value Warrants [Member]
Fair Value Measurements [Line Items]
Fair value of warrants issued			$ 16,863
Dividend yield			0.00%
Volatility rate			112.66%
Risk-free interest rate			0.78%
Expected life			6 months
Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate		80.00%
Risk-free interest rate		1.035%
Closing stock price \| $ / shares		$ 3.413
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds			$ 11,995,481		$ 256,702
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Issued warrants to purchase shares of common stock \| shares						179,241
Exchange Warrants [Member] \| Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate	111.00%
Risk-free interest rate	1.46%
Closing stock price \| $ / shares	$ 8.69
PIPE Warrants [Member]
Fair Value Measurements [Line Items]
Volatility rate			142.28%
Risk-free interest rate			1.75%
Closing stock price \| $ / shares			$ 3.62

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 11,995,481	$ 256,702
Derivative asset		1,736
Total Assets at Fair Value	11,995,481	258,438
Derivative liability		548,865
Total Liabilities at Fair Value	5,644,626	2,968,348
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	16,863	71,581
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	1,915,753	2,347,902
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	3,712,010
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	11,995,481	256,702
Total Assets at Fair Value	11,995,481	256,702
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Derivative asset
Total Assets at Fair Value
Derivative liability
Total Liabilities at Fair Value
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset		1,736
Total Assets at Fair Value		1,736
Derivative liability		548,865
Total Liabilities at Fair Value	5,644,626	2,968,348
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	16,863	71,581
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	1,915,753	$ 2,347,902
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	$ 3,712,010

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details)	12 Months Ended
	Dec. 31, 2013 USD ($)
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Balance at beginning of period	$ 1,736
Assets, Revaluation	(1,736)
Liabilities, Balance at beginning of period	2,968,348
Liabilities, Issues	19,358,108
Liabilities, Settlements	(42,144,409)
Liabilities, Revaluations	25,462,579
Liabilities, Balance at end of period	5,644,626
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	71,581
Liabilities, Revaluations	(54,718)
Liabilities, Balance at end of period	16,863
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	2,347,902
Liabilities, Settlements	(18,780,167)
Liabilities, Revaluations	18,348,018
Liabilities, Balance at end of period	1,915,753
Warrants Issued August 2013 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Issues	19,358,108
Liabilities, Settlements	(10,535,592)
Liabilities, Revaluations	(5,110,506)
Liabilities, Balance at end of period	3,712,010
Derivative Liability [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	548,865
Liabilities, Settlements	(12,828,650)
Liabilities, Revaluations	12,279,785
Derivative Asset [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Balance at beginning of period	1,736
Assets, Revaluation	$ (1,736)

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Valid portion of valuation allowance, percentage	100.00%
Number of prior years subject to examination	10 years
Accrued interest and penalties	$ 0
Reserves for uncertain tax positions	200,000	$ 200,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	75,800,000
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 2,300,000

Income Taxes (Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]
Federal	$ (93,078,760)	$ 4,586,506	$ 11,367,771
State and local	(6,128,198)	493,946	1,437,062
Deferred Income Tax Expense (Benefit), Total	(99,206,958)	5,080,452	12,804,833
Valuation allowance	99,206,958	(5,080,452)	(12,804,833)
Income Tax Benefit

Income Taxes (Schedule of Reconciliation of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]
U.S. statutory income tax rate	34.00%	34.00%	34.00%
State and local taxes, net of federal tax benefit	(8.90%)	5.20%	4.50%
Permanent differences between book and tax and other	(169.40%)	14.40%	1.50%
Valuation allowance	144.30%	(53.60%)	(40.00%)
Effective income tax rate

Income Taxes (Schedule of Deferred Tax Asset) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]
Current accruals	$ 1,998,086	$ 1,753,064
Depreciation and amortization	2,566,979	2,676,884
Deferred compensation	5,421,688	5,332,415
Net operating loss carryovers	28,045,831	127,477,179
Deferred tax assets	38,032,584	137,239,542
Valuation allowance	(38,032,584)	(137,239,542)
Net deferred tax assets

Net Loss Per Share (Computation of Basic and Diluted EPS) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net loss per common share:
Numerator for basic EPS	$ (3,962,208)	$ (56,868,442)	$ (3,006,792)	$ (4,920,147)	$ (4,316,661)	$ (1,915,281)	$ 2,806,427	$ (5,812,912)	$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Effect of dilutive securities
Numerator for diluted EPS									$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Denominator for basic EPS - weighted average shares									11,554,566	6,944,928	5,482,627
Effect of dilutive securities
Denominator for diluted EPS									11,554,566	6,944,928	5,482,627
Basic EPS	$ (0.23)	$ (4.49)	$ (0.37)	$ (0.61)	$ (0.55)	$ (0.25)	$ 0.42	$ (1.06)	$ (5.95)	$ (1.33)	$ (5.84)
Diluted EPS	$ (0.23)	$ (4.49)	$ (0.37)	$ (0.61)	$ (0.55)	$ (0.25)	$ 0.32	$ (1.06)	$ (5.95)	$ (1.33)	$ (5.84)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Net Loss Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,805,608	7,071,230	1,752,373
Restricted Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,600	68,543	52,659
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	188,947	373,899	562,733
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	588,759	529,312	98,820
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,021,302	6,099,476	1,038,161

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
Employee Benefit Plan (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Empoyee Benefit Plan [Abstract]
Maximum employer match of eligible contributions	3.00%
Defined Contribution Plan, Cost Recognized	$ 8,595	$ 395,633

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Product Warranty Provisions [Abstract]
Warranty accrual, beginning of the fiscal period	$ 653,473	$ 691,832
Warranty expense incurred	84,562	650,367
Payments made	(236,823)	(688,726)
Warranty accrual, end of the fiscal period	$ 501,212	$ 653,473

Commitments And Contingencies (Details) $ in Millions	Dec. 31, 2012 USD ($)
Commitments And Contingencies [Abstract]
Letter of credit	$ 0.1

Segment Information (Details) - USD ($)	3 Months Ended								12 Months Ended
Segment Information (Details) - USD ($)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
International
Total revenue	$ 9,068,026	$ 10,821,444	$ 9,733,407	$ 8,408,204	$ 12,204,909	$ 11,561,399	$ 10,512,898	$ 12,283,228	$ 38,031,081	$ 46,562,434	$ 41,987,432
United States [Member]
International
Total revenue									24,063,932	27,034,200	23,947,048
International [Member]
International
Total revenue									$ 13,967,149	$ 19,528,234	$ 18,040,384

Quarterly Data (Details) - USD ($)	3 Months Ended								12 Months Ended
Quarterly Data (Details) - USD ($)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Data (Unaudited) [Abstract]
Revenues	$ 9,068,026	$ 10,821,444	$ 9,733,407	$ 8,408,204	$ 12,204,909	$ 11,561,399	$ 10,512,898	$ 12,283,228	$ 38,031,081	$ 46,562,434	$ 41,987,432
Gross Profit	6,230,882	7,321,820	7,261,519	6,215,559	7,932,584	8,074,578	7,252,820	8,521,397	27,029,780	31,781,379	29,489,351
Net Loss	$ (3,962,208)	$ (56,868,442)	$ (3,006,792)	$ (4,920,147)	$ (4,316,661)	$ (1,915,281)	$ 2,806,427	$ (5,812,912)	$ (68,757,589)	$ (9,238,427)	$ (32,031,175)
Basic EPS	$ (0.23)	$ (4.49)	$ (0.37)	$ (0.61)	$ (0.55)	$ (0.25)	$ 0.42	$ (1.06)	$ (5.95)	$ (1.33)	$ (5.84)
Diluted EPS	$ (0.23)	$ (4.49)	$ (0.37)	$ (0.61)	$ (0.55)	$ (0.25)	$ 0.32	$ (1.06)	$ (5.95)	$ (1.33)	$ (5.84)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Valuation And Qualifying Accounts (Details) - USD ($)	12 Months Ended
Valuation And Qualifying Accounts (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance For Doubtful Accounts And Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 640,183	$ 667,529	$ 367,536
Additions Charged to Cost and Expenses	65,781	763	691,459
Deductions	(322,887)	(28,109)	(391,466)
Balance at the End of Year	383,077	640,183	667,529
Allowance For Inventory Valuation [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	72,639	151,157	539,518
Additions Charged to Cost and Expenses	179,803	122,783	156,852
Deductions	(172,229)	(201,301)	(545,213)
Balance at the End of Year	$ 80,213	$ 72,639	$ 151,157